Cargando…

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse

BACKGROUND: Huntington Disease (HD) is an incurable autosomal dominant neurodegenerative disorder driven by an expansion repeat giving rise to the mutant huntingtin protein (mHtt), which is known to disrupt a multitude of transcriptional pathways. Pridopidine, a small molecule in development for tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kusko, Rebecca, Dreymann, Jennifer, Ross, Jermaine, Cha, Yoonjeong, Escalante-Chong, Renan, Garcia-Miralles, Marta, Tan, Liang Juin, Burczynski, Michael E., Zeskind, Ben, Laifenfeld, Daphna, Pouladi, Mahmoud, Geva, Michal, Grossman, Iris, Hayden, Michael R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963017/ https://www.ncbi.nlm.nih.gov/pubmed/29783994 http://dx.doi.org/10.1186/s13024-018-0259-3

Ejemplares similares

Pridopidine activates neuroprotective pathways impaired in Huntington Disease
por: Geva, Michal, et al.
Publicado: (2016)

Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study
por: McGarry, Andrew, et al.
Publicado: (2020)

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease
por: Garcia-Miralles, Marta, et al.
Publicado: (2016)

Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease
por: Teo, Roy Tang Yi, et al.
Publicado: (2016)

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis
por: Ross, Colin J., et al.
Publicado: (2017)

Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose
por: Darpo, Borje, et al.
Publicado: (2023)

In Vivo Roles of a Patient-Derived Induced Pluripotent Stem Cell Line (HD72-iPSC) in the YAC128 Model of Huntington’s Disease
por: Jeon, Iksoo, et al.
Publicado: (2014)

Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease
por: Schmidt, Mandi E., et al.
Publicado: (2018)

Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease
por: Carroll, Jeffrey B, et al.
Publicado: (2011)

Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease
por: de Paula Nascimento-Castro, Cristine, et al.
Publicado: (2018)

Temporal Characterization of Behavioral and Hippocampal Dysfunction in the YAC128 Mouse Model of Huntington’s Disease
por: de Paula Nascimento-Castro, Cristine, et al.
Publicado: (2022)

Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease
por: Francardo, Veronica, et al.
Publicado: (2019)

Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease
por: Van Raamsdonk, Jeremy M, et al.
Publicado: (2006)

Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma
por: Geva, Michal, et al.
Publicado: (2021)

Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)
por: Kim, Jason, et al.
Publicado: (2020)

Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
por: Ellrichmann, Gisa, et al.
Publicado: (2011)

Transplantation of patient-derived adipose stem cells in YAC128 Huntington's disease transgenic mice
por: Im, Wooseok, et al.
Publicado: (2010)

Neonatal Iron Supplementation Induces Striatal Atrophy in Female YAC128 Huntington’s Disease Mice
por: Berggren, Kiersten L., et al.
Publicado: (2016)

Age-related mitochondrial alterations in brain and skeletal muscle of the YAC128 model of Huntington disease
por: Bečanović, Kristina, et al.
Publicado: (2021)

Beyond Motor Deficits: Environmental Enrichment Mitigates Huntington’s Disease Effects in YAC128 Mice
por: Plácido, Evelini, et al.
Publicado: (2023)

pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model
por: Xu, Xiaohong, et al.
Publicado: (2020)

C57BL/6 Background Attenuates mHTT Toxicity in the Striatum of YAC128 Mice
por: Back, Michaela K., et al.
Publicado: (2021)

DAPK1 Promotes Extrasynaptic GluN2B Phosphorylation and Striatal Spine Instability in the YAC128 Mouse Model of Huntington Disease
por: Schmidt, Mandi E., et al.
Publicado: (2020)

Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine
por: Wang, Shao-Ming, et al.
Publicado: (2022)

Author Correction: Age-related mitochondrial alterations in brain and skeletal muscle of the YAC128 model of Huntington disease
por: Bečanović, Kristina, et al.
Publicado: (2021)

Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1(G93A) Model
por: Ionescu, Ariel, et al.
Publicado: (2019)

Neural stem cells derived from the developing forebrain of YAC128 mice exhibit pathological features of Huntington’s disease
por: Li, Endan, et al.
Publicado: (2020)

Differential Synaptic and Extrasynaptic Glutamate-Receptor Alterations in Striatal Medium-Sized Spiny Neurons of Aged YAC128 Huntington’s Disease Mice
por: Botelho, Eliã P., et al.
Publicado: (2014)

Metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease
por: Rabinovich‐Guilatt, Laura, et al.
Publicado: (2017)

Pridopidine Reverses Phencyclidine-Induced Memory Impairment
por: Sahlholm, Kristoffer, et al.
Publicado: (2018)

A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease
por: Kotowska-Zimmer, Anna, et al.
Publicado: (2022)

Correction: Differential Synaptic and Extrasynaptic Glutamate-Receptor Alterations in Striatal Medium-Sized Spiny Neurons of Aged YAC128 Huntington's Disease Mice
Publicado: (2017)

Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease
por: Waters, Susanna, et al.
Publicado: (2018)

In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease
por: Callahan, Joshua W., et al.
Publicado: (2011)

Solid Lipid Curcumin Particles Protect Medium Spiny Neuronal Morphology, and Reduce Learning and Memory Deficits in the YAC128 Mouse Model of Huntington’s Disease
por: Gharaibeh, Abeer, et al.
Publicado: (2020)

Letter to the Editor response: Nygaard et al.
por: Towfic, F., et al.
Publicado: (2017)

Biobanking in Israel 2016–17; expressed perceptions versus real life enrollment
por: Koren, Gideon, et al.
Publicado: (2017)

Similar striatal gene expression profiles in the striatum of the YAC128 and HdhQ150 mouse models of Huntington’s disease are not reflected in mutant Huntingtin inclusion prevalence
por: Bayram-Weston, Zubeyde, et al.
Publicado: (2015)

Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Induced Pluripotent Stem Cell-Derived Neural Stem Cell Transplantations Reduced Behavioral Deficits and Ameliorated Neuropathological Changes in YAC128 Mouse Model of Huntington's Disease
por: Al-Gharaibeh, Abeer, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6d95l78kvhgrn4t6dsljo4t8bc